Market Intelligence, Non-Hormonal Contraceptive Development, and High-Purity Bromodomain Reagents for Selective Targeting.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BRDT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (BD1 Domain) | BRDT (Bromodomain 1) Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View BRDT Products |
| Antigen (BD2 Domain) | BRDT (Bromodomain 2) Recombinant Protein. High purity (>95%), Theoretical MW verified. For selective binding assays. | View BRDT Products |
| Gene Delivery | BRDT Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. CMV promoter. | View BRDT Products |
| Benchmark Ab | Anti-BRDT Monoclonal Antibody (Clone 8C3). Recombinant positive control for Western/IP. | View BRDT Products |
| Validator | BRDT siRNA Set. For knockdown verification and specificity controls. | View BRDT Products |
| Related Target (Selectivity) | BRD2 (BD1/BD2 Domains). Essential for counter-screening against pan-BET inhibition. | View BRD2 Products |
| Related Target (Selectivity) | BRD4 (BD1/BD2 Domains). Critical safety counter-target; BRD4 inhibition causes toxicity. | View BRD4 Products |
| Related Target (Selectivity) | BRD3 (BD1/BD2 Domains). Additional BET family selectivity panel member. | View BRD3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BET Family Selectivity (BRD2/3/4 vs BRDT) | Homologous Bromodomain Panel available (BD1 & BD2 constructs) with >95% purity for parallel SPR/TR-FRET screening |
| Domain Selectivity (BD1 vs BD2) | Separate BD1 and BD2 domain proteins available for dissecting dual-bromodomain pharmacology |
| Acetyl-Lysine Binding Validation | Sequence Verified bromodomain constructs with native folding confirmed by Circular Dichroism |
| Cell-Based Target Engagement | Lentivirus Premade Particles for stable BRDT-overexpressing cell lines; Endotoxin Controlled (<10^4 TU/ng) |
| PROTAC Degradation Validation | Sequence-verified Promise-ORF lentivirus for stable cellular assay construction |
| False Positives in Screening | Validated siRNA included for cellular specificity checks |
Global Clinical Landscape & Future Outlook
The race for BRDT-targeted therapeutics represents a paradigm shift in male contraceptive development, moving away from hormonal suppression toward reversible germ cell-specific mechanisms. The seminal BET inhibitor JQ1 was first shown to penetrate the blood-testis barrier and inhibit BRDT, inducing reversible spermatogenesis arrest. However, JQ1 and related pan-BET inhibitors (targeting BRD2/3/4/DT) cause unacceptable toxicity (e.g., thrombocytopenia) due to BRD4 cross-reactivity. The next wave of R&D is sharply focused on BRDT-selective small molecules and PROTAC degraders, aiming to exploit the structural nuances of the BRDT bromodomains to achieve safety profiles suitable for healthy populations. As first-in-class selective BRDT inhibitors enter preclinical safety studies, the critical differentiator will be the ability to discriminate between BD1 and BD2 domains across the entire BET family. While pan-BET inhibitors have advanced in oncology, BRDT-selective inhibitors are poised to open a new therapeutic avenue in non-hormonal male contraception and testicular germ cell tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective) | Bayer, SGC, Academic Consortia, Biotechs | Non-Hormonal Male Contraception | BD1/BD2 Selectivity Panel (Need purified individual domains from BRDT vs BRD4) |
| PROTAC Degrader | Targeted Degradation Firms, Academic Research | Male Contraception, Testicular Cancer | Ternary Complex Validation (Need uniformly tagged antigens; E3 ligase reagents like CRBN/VHL) |
| Pan-BET Inhibitor | Oncology Pharma | Hematologic Cancers | Counter-screening Assay (Need BRDT as off-target liability control; full BET family panel) |
Live BRDT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: